Perrigo Company (PRGO) revenue breakdown

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $2.1B

By segment, CSCA is the largest at 61% of fiscal 2025 revenue; CSCI grew fastest, 2% a year over 8 years.

By region, United States is the largest at 60% of fiscal 2025 revenue; Europe grew fastest, 0% a year over 9 years.

Revenue by segment

Fiscal years, as Perrigo Company reports them in its 10-K filings; fiscal 2025 total $4.3B.

Segments2016201720182019202020212022202320242025Share
CSCA$2.5B$2.4B$2.4B$2.5B$2.7B$2.7B$2.9B$3.0B$2.7B$2.6B 61%
CSCI—$1.4B$1.4B$1.4B$1.4B$1.4B$1.5B$1.7B$1.7B$1.7B 39%
CHCI$1.7B————————— —
RX$1.0B$1.1B$921M——————— —
Other(1)$78M————————— —
Other—$56M———————— —

Revenue by region

Fiscal years, as Perrigo Company reports them in its 10-K filings; fiscal 2025 total $4.3B.

Regions2016201720182019202020212022202320242025Share
United States$3.4B$3.3B$3.1B$2.4B$2.6B$2.6B$2.9B$2.9B$2.6B$2.5B 60%
Europe$1.6B$1.3B$1.3B$1.3B$1.4B$1.4B$1.5B$1.6B$1.6B$1.6B 38%
All Other Countries$346M$330M$286M$174M$159M$180M$107M$116M$120M$97M 2%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PRGO.
Open PRGO in Investingly

Questions

Where does Perrigo Company make its money?

In fiscal 2025, by segment: CSCA $2.6B, CSCI $1.7B.

From Perrigo Company's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.